Showing results (101-110 of 208) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.Dermatology and Therapy|November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic MelanomaWim H J Kruit, Stefan Suciu, Brigitte Dreno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.International Journal of Cancer|September 28, 2002
The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective studyJean Jacques Grob, Marie Aleth Richard, Johany Gouvernet, et al.The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.Blood Advances|October 23, 2020
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cellsFlorent Amatore, Nicolas Ortonne, Marc Lopez, et al.European Journal of Dermatology : EJD|November 18, 2015
Defining and recognising locally advanced basal cell carcinomaJean Michel Amici, Maxime Battistella, Marie Beylot-Barry, et al.Pageof 21